Allianz Asset Management
BNGO icon

Allianz Asset Management’s Bionano Genomics BNGO Stock Holding History

Allianz Asset Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,058
Closed -$1.7M – 1910
2022
Q2 		$1.7M Sell
2,058
-2
-0.1% -$2.06K ﹤0.01% 1475
2022
Q1 		$3.19M Buy
+2,060
New +$2.78M ﹤0.01% 1412
2021
Q2 		– Sell
-88
Closed -$427K – 2394
2021
Q1 		$427K Buy
+88
New +$496K ﹤0.01% 1951

Other funds holding BNGO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Allianz Asset Management's BNGO Position: Q3 2022 in Review

Allianz Asset Management sold out of Bionano Genomics (BNGO) in Q3 2022, closing a stake of 2,058 shares — an estimated $1.7M sold.

Allianz Asset Management first reported a position in BNGO in Q1 2021 and held it in 3 quarters. The position peaked at $3.19M in Q1 2022. 140 funds tracked by Wall St. Rank hold BNGO as of Q3 2022.

  • Allianz Asset Management reported no remaining Bionano Genomics position as of Q3 2022 after selling out during the quarter.
  • Allianz Asset Management sold 2,058 Bionano Genomics shares in Q3 2022, an estimated $1.7M.
  • Allianz Asset Management first reported a position in Bionano Genomics in Q1 2021 and held it in 3 quarters.
  • Allianz Asset Management's Bionano Genomics position peaked at $3.19M in Q1 2022.
  • 140 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2022.

Based on Allianz Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.